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Abstract 
Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle worldwide and a major 
obstacle to profitable beef production. Use of chlortetracycline-medicated feed to control active 
anaplasmosis infections during the vector season has raised concerns about the potential emergence of 
antimicrobial resistance in bacteria that may pose a risk to human health. Furthermore, the absence of 
effectiveness data for a commercially available, conditionally licensed anaplasmosis vaccine is a major 
impediment to implementing anaplasmosis control programs. The primary objective of this study was to 
develop a single-dose vaccine delivery platform to produce long-lasting protective immunity against 
anaplasmosis infections. Twelve Holstein steers, aged 11-12 weeks, were administered a novel 3-stage, 
single-dose vaccine against Anaplasma marginale (Am) major surface protein 1a. The vaccine consisted 
of a soluble vaccine administered subcutaneously (s.c.) for immune priming, a vaccine depot of a 
biodegradable polyanhydride rod with intermediate slow release of the vaccine for boosting immune 
response, and an immune-isolated vaccine platform for extended antigen release (VPEAR implant) 
deposited s.c. in the ear. Six calves were randomly assigned to two vaccine constructs (n=3) that featured 
rods and implants containing a combination of two different adjuvants, diethylaminoethyl (DEAE)-Dextran 
and Quil-A (Group A). The remaining 6 calves were randomly assigned to two vaccine constructs (n=3) 
that featured rods and implants containing the same adjuvant (either DEAE-Dextran or Quil A) (Group B). 
Twenty one months post-implantation, calves were challenged intravenously with Am stabilate and were 
monitored weekly for signs of fever, decreased packed cell volume (PCV) and bacteremia. Data were 
analyzed using a mixed effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC). 
Calves in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection. Calves in 
Group A were less likely to require antibiotic intervention compared with calves in Group B (P = 0.014). 
Results indicate that calves exhibited diminished clinical signs of anaplasmosis when antigen was 
delivered with a combination of adjuvants as opposed to a single adjuvant. This demonstrates the 
feasibility of providing long lasting protection against clinical bovine anaplasmosis infections using a 
subcutaneous ear implant vaccine construct. 
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ABSTRACT: Bovine anaplasmosis is the most prevalent tick-transmitted disease of cattle 
worldwide and a major obstacle to profitable beef production.  Use of chlortetracycline-
medicated feed to control active anaplasmosis infections during the vector season has raised 
concerns about the potential emergence of antimicrobial resistance in bacteria that may pose 
a risk to human health.  Furthermore, the absence of effectiveness data for a commercially 
available, conditionally licensed anaplasmosis vaccine is a major impediment to 
implementing anaplasmosis control programs.  The primary objective of this study was to 
develop a single-dose vaccine delivery platform to produce long-lasting protective immunity 
against anaplasmosis infections.  Twelve Holstein steers, aged 11-12 weeks, were 
administered a novel 3-stage, single-dose vaccine against Anaplasma marginale (Am) major 
surface protein 1a.  The vaccine consisted of a soluble vaccine administered subcutaneously 
(s.c.) for immune priming, a vaccine depot of a biodegradable polyanhydride rod with 
intermediate slow release of the vaccine for boosting immune response, and an immune-
isolated vaccine platform for extended antigen release (VPEAR implant) deposited s.c. in the 
ear.  Six calves were randomly assigned to two vaccine constructs (n=3) that featured rods 
and implants containing a combination of two different adjuvants, diethylaminoethyl 
(DEAE)-Dextran and Quil-A (Group A).  The remaining 6 calves were randomly assigned to 
two vaccine constructs (n=3) that featured rods and implants containing the same adjuvant 
(either DEAE-Dextran or Quil A) (Group B).  Twenty one months post-implantation, calves 
were challenged intravenously with Am stabilate and were monitored weekly for signs of 
fever, decreased packed cell volume (PCV) and bacteremia.  Data were analyzed using a 
mixed effects model and chi-squared tests (SAS v9.04.01, SAS Institute, Cary, NC).  Calves 
in Group A had higher PCV than calves in Group B (P = 0.006) at day 35 post-infection.  
Calves in Group A were less likely to require antibiotic intervention compared with calves in 
Group B (P = 0.014).  Results indicate that calves exhibited diminished clinical signs of 
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anaplasmosis when antigen was delivered with a combination of adjuvants as opposed to a 
single adjuvant.  This demonstrates the feasibility of providing long lasting protection against 
clinical bovine anaplasmosis infections using a subcutaneous ear implant vaccine construct. 
 
Key Words: Anaplasma marginale, anaplasmosis, Bos taurus, cattle, implant, vaccine  
 
INTRODUCTION 
Anaplasmosis, caused by the rickettsial hemoparasite, Anaplasma marginale (Am), is the most 
prevalent tick-transmitted disease of cattle worldwide and causes significant disease loss to beef 
producers in the United States (Uilenberg, 1995; Kocan et al. 2003).  In the absence of an effective 
vaccine, control of anaplasmosis infection is predicated on the administration of low doses of in-feed 
chlortetracycline for several months (Reinbold et al. 2010b).  As of January 2017, control of active 
anaplasmosis using in-feed chlortetracycline requires veterinary oversight in the form of a veterinary 
feed directive (VFD).  As a result, federal law restricts this medicated feed to use by or on the order 
of a licensed veterinarian (FDA, 2019).  The VFD places an additional regulatory burden on livestock 
producers and makes anaplasmosis control in extensive and smaller livestock operations especially 
challenging.   
Vaccination strategies to control anaplasmosis are urgently needed to assist livestock producers 
in combating this disease.  Major surface protein (MSP) 1a (MSP1a) is one of six MSP previously 
described on Am derived from bovine erythrocytes (Palmer et al. 2001) and is involved in immunity 
to Am infection in cattle (Palmer et al. 1987).  Previous work has shown that cattle vaccinated with 
erythrocyte-derived Am antigens demonstrated preferential recognition for MSP1a (Brown et al. 
2001).  The present study was conducted to determine the optimal delivery and adjuvant 
combination of Am MSP1a using a 3-stage vaccine administered as a single injection and long-term 
subcutaneous (s.c.) ear implant.  The unique vaccine implant design allows for a sustained release of 
the target antigen with an immunoregulatory design to minimize tolerance and achieve long-term 
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immunization in a single dose.  We hypothesize that this device will mimic the life-long concomitant 
immunity associated with persistent Am infection after field exposure. 
 
MATERIALS AND METHODS 
All animal studies were conducted under an approved Institutional Animal Care and Use 
Committee (IACUC) protocol (IACUC #: 3959) on file at Kansas State University, Manhattan, Kansas. 
Antigen 
The peptide antigen R1OK was designed from an Am strain originally isolated from a cow in 
Oklahoma as previously described by Blouin et al. (2000) and characterized by de la Fuente et al. 
(2003a).  The MSP1a genotype of this Am Oklahoma strain is K;S-C-H.  The multiple antigenic peptide 
(MAP) for this vaccine was the R1OK peptide, NH2-ADGSSAGGQQQESSVSSQSDQASTSSQLG-COOH, 
derived from MSP1a tandem repeat K;S (de la Fuente et al. 2003a), which was synthesized as an 8-
subunit MAP (Biosynthesis, Lewisville, TX) and shipped as a powder.  
Priming Solubilization 
To yield an immune-priming dose, 2 mg of R1OK-MAP was solubilized in 2 mL of MES buffer [0.1 
M 2-(N-morpholino) ethanesulfonic acid, 0.9% sodium chloride, pH 4.7] and linked via 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride to 2 mg Imject Blue carrier protein (BP) (Thermo 
Fisher Scientific, Waltham, MA) in 1 mL of MES buffer following manufacturer’s recommendations.  
The conjugate was washed through a polyethersulfone 3K molecular weight cutoff protein 
concentrator (Pierce, Thermo Fisher Scientific) three times in pH 7.42 phosphate-only buffer 
prepared according to manufacturer’s instructions (Thermo Fisher Scientific).  The soluble vaccine 
consisted of 300 µg R1OK-MAP in 1.0 mL pH 7.42 phosphate-only buffer mixed with 1.0 mL 
Montanide ISA 61 VG adjuvant (Seppic, Paris, France) for a final volume of 2 mL per injection.  
Rod and implant design  
The boosting dose relied on a bioerodible polyanhydride (PA) rod 15mm long and 4mm in 
diameter composed of 20% 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 80% 1,6-bis(p-
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carboxyphenoxy) hexane (CPH) (20:80 CPTEG:CPH) (Schaut et al. 2018).  The molecular weight and 
copolymer composition of the 20:80 CPTEG:CPH copolymer were 6.618 kDa and 23:77, respectively.  
The boosting dose rod consisted of 208 mg of PA, 100 µg of R1OK-MAP, and 100 mg of 
diethylaminoethyl-dextran (DEAE-Dextran) or 500 µg Quil-A (Sigma-Aldrich, Saint Louis, MO) as 
indicated.  The VPEAR implant (Jones et al., 2016) for long-term release (up to 3 years) consisted of 
140 mg of PA, 100 µg of R1OK-MAP and 100 mg of DEAE-Dextran or 500 µg Quil-A as indicated.  Dry 
mixtures of all components were pressed in a custom-made mold at 0.5 tons-on-ram for 5 s, using a 
hydraulic press (International Crystal Laboratories Inc., Garfield, NJ).  The implant was designed and 
formulated as previously described (Schaut et al. 2018).  All but three calves required implant 
replacement after initial rejection.  Rejections were preceded by local inflammation and formation 
of an abscess around the implant sites.  Implant replacements were of identical design to the original 
implant, except the amount of adjuvant was reduced to either 10 mg of DEAE-Dextran or 50 µg of 
Quil-A. 
Study Animals 
A cohort of 12 Holstein steers ranging from 11-12 weeks of age, weighing 102.1 ± 2.3 kg (mean ± 
SEM) was enrolled in the project.  Calves were randomly assigned to vaccine treatment groups using 
the RAND function in a spreadsheet program (Microsoft Excel, Richmond, WA).  Six calves were 
assigned to two vaccine constructs that featured rods and implants containing a combination of 
different adjuvants (DEAE-Dextran and Quil-A) (Group A).  The remaining 6 calves were randomly 
assigned to two vaccine constructs that featured rods and implants containing the same adjuvant 
(either DEAE-Dextran or Quil A) (Group B).  All calves received an initial soluble vaccine priming dose 
s.c. before implantation (See Table 1).  As this was a proof-of-concept study conducted over 2 years 
and animal numbers were limited, we did not enroll a negative control group to evaluate the 
differences in composition of the vaccine constructs.   
Animal vaccinations 
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The soluble vaccine was administered into the s.c. tissue on the right side of the neck.  
Immediately afterward, the rod was inserted into the s.c. tissue at the base of the right ear pinna 
through a six-gauge needle; the implant was then manually inserted through the same incision.  The 
incision was closed with a single suture.  Reimplantation, when required, was done into the left 
(contralateral) ear, five weeks after the initial implant.  All but three calves required reimplantation 
within the first 5 weeks of the study with devices containing a reduced adjuvant load.  All implants 
were subsequently maintained for the duration of the study, suggesting that rejection may have 
been due to excessive activation of an immune response to the initial implant device.  
Reimplantation was not believed to impact total antigen delivery as the rate of release from the 
implants was engineered to remain consistent for the duration of the study regardless of whether 
the device was reimplanted.   
Anaplasma marginale infection challenge  
A cryopreserved field isolate of Am, with the MSP1a genotype M-F-F, was administered IV at 21 
months after vaccination to infection challenge immunized animals.  This represented day zero of 
the infection challenge phase of the study.  Calves weighed a mean ± SEM of 632.7 kg ± 16.3 kg and 
were approximately 24 months of age at the time of challenge.  The Am challenge isolate was 
obtained from a persistently-infected cow in Oklahoma in 2017.  Briefly, to prepare the 
cryopreserved Am isolate, 60 mL of blood from the donor cow was collected into a blood bag 
containing heparin and sub-inoculated into a splenectomized calf to amplify Am.  The resulting 
infected red blood cells were washed three times in phosphate buffered saline (PBS), resuspended 
1:1 in a stabilate buffer (31.2% dimethylsulfoxide in 1X PBS) after the final wash, and stored in liquid 
nitrogen as described by Love (1972).  Two milliliters of cryopreserved Am (M-F-F genotype) 
stabilate were intravenously inoculated into the jugular vein of each vaccinated steer.  The target 
Am challenge dose was approximately 2 x 109 bacteria per inoculation. 
Sampling 
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Beginning at day zero of the infection challenge component of the study, approximately 20 mL 
of whole blood was drawn from the jugular or coccygeal vein into evacuated tubes (Vacutainer, 
Becton Dickinson, Franklin Lakes, NJ) containing EDTA (1.8 mg/mL whole blood) or no anticoagulant 
once weekly post-infection to monitor development of anemia, bacteremia, and antibody response 
to Am.  Anemia was evaluated by quantifying packed cell volume (PCV) from whole blood that was 
collected into EDTA tubes and centrifuged (Micro-Hematocrit Centrifuge CMH30, UNICO, Dayton, 
NJ).  Development of bacteremia was monitored by PCR and microscopic examination of Wright-
Giemsa-stained blood smears (HEMA-3, Fisher HealthCare, Pittsburgh, PA).  Total genomic DNA was 
extracted from 100 µL of whole blood collected into EDTA tubes using the Quick-DNA Miniprep Kit 
(Zymo Research, Irvine, CA) according to manufacturer instructions, and DNA was eluted in 35 µL of 
DNA Elution Buffer.  A quantitative, real-time PCR (qPCR) assay targeting a portion of the single-copy 
Am gene MSP5 was used to quantify Am infection levels in blood as previously described (Hammac 
et al. 2013).  Quantitative specificity for this qPCR assay is 100 copies per template and qualitative 
sensitivity is 10 copies per template.  Serum was centrifuged at 2,000 x g for 10 min at 20°C from 
whole blood collected into evacuated tubes containing no anticoagulant.  Serum samples were 
submitted to the Iowa State University Veterinary Diagnostic Laboratory (Ames, IA) for Am 
serological screening using a commercial cELISA that detects host antibodies produced against Am 
MSP5 (Catalog No: 283-2, VMRD, Pullman, WA).  
Animal Health 
Anaplasmosis is potentially fatal, and animal health was monitored closely to determine need 
for antibiotic intervention.  Animal PCV and rectal temperature were measured twice per week.  
Veterinary exams were performed if: temperatures measured greater than 39.2oC or less than 
36.7oC, PCV was measured at less than 22%, respiration rate was measured at greater than 60 
breaths per minute, inappetence was noted for more than 24 hours, or if severe depression was 
observed for more than 24 hours.  Veterinary physical exams included verification of symptoms in 
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addition to assessment of depressed mentation and icteric mucus membranes.  Cattle were treated 
with a single label dose of 200 mg/mL oxytetracycline (Bio-Mycin 200, Boehringer Ingelheim 
Vetmedica Inc, Duluth, GA) at 20 mg/kg body weight if two or more of the preceding symptoms 
were displayed as determined by the attending veterinarian (EJR).  If an animal required antibiotic 
intervention, then vaccination was deemed a failure.  
Statistical Analysis 
Outcome variables PCV, cELISA percent inhibition, bacteremia, and body temperature were 
analyzed using a generalized linear mixed model incorporating both fixed effects and random effects 
(PROC GLMMIX; SAS university edition v9.04.01, SAS Institute, Cary, NC).  All of these responses best 
fit to log-normal models.  Day post-infection, vaccine treatment group (each of four vaccine 
treatments tested), vaccine construct (Group A or B; depending on combination or single adjuvants), 
and their interactions were analyzed as fixed effects in the model with cattle nested in vaccine 
construct designated as a random effect.  Where there was evidence for a vaccine construct by day 
post-infection interaction, simple effect comparisons of least squares means were conducted using 
Tukey-Kramer adjustment for multiple comparison.  For all outcomes, statistical significance was set 
a priori at P < 0.05.   Two-tailed chi-squared tests, with and without Yate’s corrections, were used to 
compare disease outcome between vaccine constructs (combination adjuvants vs. single adjuvant).  
A Fisher’s exact test was also used for comparison between vaccine constructs.      
 
RESULTS AND DISCUSSION 
The effect of vaccine treatment group alone was examined but no differences were found when 
comparing bacteremia (P = 0.136) or body temperature (P = 0.068).  Animals administered the 
combination adjuvant vaccine construct had higher PCV than those receiving the single adjuvant 
vaccine construct at day 35 post-infection (P = 0.006) (Figure 1).  Bacteremia peak coincided with 
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PCV nadir (Figure 1).  It is noteworthy that a chi-squared test without Yate’s correction revealed that 
animals vaccinated with combination adjuvants (vaccine construct A) were less likely to require 
antibiotic intervention compared with calves vaccinated with single adjuvants (vaccine construct B) 
(P = 0.014).  A Fisher’s exact test revealed a similar trend (P = 0.061), as did a chi-squared test with 
Yate’s correction (P = 0.066).  These results indicate that calves exhibited diminished clinical signs of 
anaplasmosis when vaccine antigen was delivered with a combination of adjuvants as opposed to a 
single adjuvant.   
These results are in agreement with previous studies that indicated that immunization with 
native MSP1 (a heterodimer containing disulfide and noncovalently bonded polypeptides MSP1a and 
MSP1b) of the erythrocytic stage of Am conferred protection against pathogen challenge (Palmer et 
al. 1986).  Likewise, Hope et al. (2004) demonstrated the value of using multiple adjuvants to confer 
immunity and decrease the need for antibiotic intervention in infected animals.  This may be due to 
a broader repertoire of immune effector cells being stimulated by multiple adjuvants.  Previous work 
has suggested that Quil-A (a heterogenous fraction of saponin) induces activation of dendritic cells 
and leads to strong antibody and T cell responses (Maraskovsky et al., 2009).  Though mode of action 
hasn’t been studied in detail, DEAE-Dextran has shown antibody enhancing properties in anti-fertility 
vaccines (Vizcarra et al., 2012) and appears to stimulate antigen-specific antibodies and eosinophilia 
when used in helminth vaccines (Piedrafita et al., 2013).   
Assuming vaccine efficacy is based on a reduced need for antimicrobial therapy and increased 
survival, our data indicate that the use of multiple adjuvants in the vaccine construct could limit 
disease severity.  Though caution is necessary considering the small sample size, it is noteworthy 
that 100% (6/6) of the animals vaccinated using a single adjuvant (DEAE-Dextran or QuilA) required 
antibiotic intervention during the study, compared to only 33% (2/6) of animals vaccinated using 
combination adjuvants (DEAE-Dextran and QuilA).   
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Despite the documented negative impact of anaplasmosis in cattle herds (Alderink et al. 1982), 
there remains no effective means of disease prevention.  Controlling the disease once endemic is 
challenging, as transmission of Am can be mediated through biological vectors such as ticks 
(Dikmans, 1950), mechanical vectors such as horseflies (Baldacchino et al. 2014), blood-
contaminated fomites such as needles (Reinbold et al. 2010a), or transplacentally from cow to calf 
during gestation (Zaugg, 1985).  Average weight loss associated with disease progression is reported 
to be 190 lbs. (Alderink et al. 1982) with adult (>2yrs of age) cattle being more susceptible to severe 
clinical disease and death (Kocan et al. 2003).  Symptoms diminish in surviving animals, but 
recovered cattle maintain low, sometimes undetectable, levels of infection (Coetzee et al. 2005).  
These carrier animals subsequently serve as local reservoirs for disease transmission (Swift and 
Thomas, 1983).  Previous work has estimated that, when introduced to a naïve herd, anaplasmosis 
can result in a 3.6% reduction in calf crop, a 30% increase in cull rate, and a 3% mortality rate in 
clinically infected adult cattle (Alderink et al. 1982).  In spite of these challenges, strategies to control 
anaplasmosis have not changed markedly in the last several decades (Kocan et al. 2003).   
Though not available in the U.S., use of live vaccines containing attenuated or less pathogenic 
strains of Am or A. centrale for the control of clinical anaplasmosis is widespread in many parts of 
the world (Rogers et al. 1988).  These vaccines are predicated on the principle of concomitant 
immunity, the paradoxical immune status in which resistance to reinfection coincides with the 
persistence of the original infection.  Live vaccine-vaccinated cattle develop persistent infections 
which induce lifelong protective immunity in cattle such that revaccination is usually not required 
(Shkap et al. 2008).  Although generally effective, use of live Am vaccines is not legal in the U.S.  
There are currently no USDA-approved vaccines for protection against Am infection or lowering 
disease severity.  An experimental killed vaccine is available in 14 U.S. states, but no efficacy data for 
this vaccine are available (Aubry and Geale, 2011).  Killed vaccines that contain purified Am 
organisms from erythrocytes are expensive to manufacture, may have the potential to induce 
isoimmune erthrolysis following repeated administration, have unknown efficacy against 
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heterologous strains, and usually require annual revaccination (Kocan et al. 2003).  Thus, there 
remains no vaccine universally accepted as safe and effective against bovine anaplasmosis (Hammac 
et al. 2013).   
This study tested the efficacy of a set of s.c. vaccine implants to protect against the development 
of antibiotic-intervention-requiring clinical anaplasmosis.  Work presented here agrees with previous 
studies using cell culture-derived Am antigens (Kocan et al. 2001).  Six MSPs of Am have been 
identified on erythrocyte-derived organisms (Kocan et al. 2003).  The MSP1a is an Am adhesin for 
both bovine erythrocytes and tick cells (de La Fuente et al. 2003b). MSP1a has been explored as a 
vaccine target for Am because the individual tandem repeats contain B and T cell epitopes (Cabezas-
Cruz et al. 2015).  Cattle immunized with erythrocyte-derived Am have been shown to have a 
preferential antibody response to MSP1a (Brown et al. 2001).  Immunization of cattle with MSP1a 
has also been shown to reduce infection of Am for the tick Dermacentor variabilis (de La Fuente et 
al. 2003c).  The tandem repeats of the MSP1a subunit-based vaccines with Am MSP1a functional 
motifs have also been shown to induce a balanced humoral and cellular immune response in mice 
(Santos et al. 2013).  It is possible that we would have observed a more robust protective response if 
we had used an Am strain that contained the K;S tandem repeat sequence, as the B and T cell 
epitopes differ between K;S, M and F tandem repeats (Catanese et al. 2016).   
 In the present study, our group demonstrated the feasibility of a subunit-based vaccine 
delivered in a single, subcutaneous ear implant 21 months prior to disease challenge.  Future work 
may expand upon this observation by incorporating other conserved antigens, such as those 
previously identified (Riding et al. 2003) utilizing a similar vaccine delivery platform.  Future work 
may also establish an optimal adjuvant concentration in order to achieve high immunogenicity 
without implant rejection.   
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Table 1. Random assignment of calves to vaccine treatment groups.   
Vaccine 
Treatment 
Groupa  
(n = 3) 
Vaccine 
Constructb 
 (n = 6) 
Priming 
Dose (300 
ug R1OK-
MAP-BP/ 
Montanide) 
 Boosting 
dose (rod) 
adjuvant 
Implant 
adjuvant 
Vaccine 
Outcome 
(Failure/ 
Treatment) 
1 B 1 dose s.c. DEAE-
dextran 
DEAE-
dextran 
3/3 
2 B 1 dose s.c. Quil A Quil A 3/3 
3 A 1 dose s.c. Quil A DEAE-
dextran 
1/3 
4 A 1 dose s.c. DEAE-
dextran 
Quil A 1/3  
 
a Calves were randomly assigned to one of four vaccine treatment groups 
b Calves were divided between two vaccine constructs (A or B) denoting single or combination 
adjuvants - diethylaminoethyl-Dextran (DEAE-Dextran) and Quil A 
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Figure 1.  Mean (± SEM) bacteremia and packed cell volume (PCV) of vaccinated animals 
challenged with Anaplasma marginale.  (A) PCV is shown over time and separated by vaccine 
construct.  (B) Bacteremia is shown over time and separated by vaccine construct.  PCV was 
significantly higher among animals within the combination adjuvant construct than those within 
the same adjuvant construct at day 35.  * P = 0.006. 
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Fig1-2 SEM 300dpi 
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